GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Price-to-Free-Cash-Flow

ARCA biopharma (FRA:HQ10) Price-to-Free-Cash-Flow : N/A (As of May. 27, 2025)


View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Price-to-Free-Cash-Flow?

As of today (2025-05-27), ARCA biopharma's share price is €25.92. ARCA biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €-5.30. Hence, ARCA biopharma's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for ARCA biopharma's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:HQ10's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.63
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

ARCA biopharma's Free Cash Flow per Share for the three months ended in Jun. 2024 was €-2.02. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-5.30.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 40.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 46.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 42.70% per year.

During the past 13 years, ARCA biopharma's highest 3-Year average Free Cash Flow per Share Growth Rate was 62.20% per year. The lowest was 18.50% per year. And the median was 49.90% per year.


ARCA biopharma Price-to-Free-Cash-Flow Historical Data

The historical data trend for ARCA biopharma's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARCA biopharma Price-to-Free-Cash-Flow Chart

ARCA biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ARCA biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ARCA biopharma's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, ARCA biopharma's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ARCA biopharma's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Price-to-Free-Cash-Flow falls into.


;
;

ARCA biopharma Price-to-Free-Cash-Flow Calculation

ARCA biopharma's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=25.92/-5.295
=N/A

ARCA biopharma's Share Price of today is €25.92.
ARCA biopharma's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.30.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ARCA biopharma  (FRA:HQ10) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ARCA biopharma Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ARCA biopharma Business Description

Traded in Other Exchanges
N/A
Address
10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021
ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines